Heat Biologics, which is developing cellular therapeutic vaccines for cancer therapy, filed on Monday with the SEC to raise up to $20 million in an initial public offering.
The Chapel Hill, NC-based company, which was founded in 2008 and has been awarded $0.6 million in grants since inception, plans to list on the NASDAQ under the symbol HEAX. Heat Biologics initially filed confidentially on December 24, 2012. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
